Clinical Trial
Inhibition of endopeptidase EC 3.4.24.11 by candoxatril lowered blood pressure and increased urinary but not plasma atrial natriuretic peptide in essential hypertension
Affiliations
- PMID: 8158355
Item in Clipboard
Clinical Trial
Inhibition of endopeptidase EC 3.4.24.11 by candoxatril lowered blood pressure and increased urinary but not plasma atrial natriuretic peptide in essential hypertension
J Hypertens Suppl.
1993 Dec.
No abstract available
Similar articles
-
Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension.J Hypertens. 1992 Jul;10(7):607-13. J Hypertens. 1992. PMID: 1321186 Clinical Trial.
-
Candoxatril, an orally active neutral endopeptidase inhibitor, raises plasma atrial natriuretic factor and is natriuretic in essential hypertension.J Hypertens. 1992 Mar;10(3):271-7. doi: 10.1097/00004872-199203000-00011. J Hypertens. 1992. PMID: 1315825 Clinical Trial.
-
Dual inhibition of angiotensin converting enzyme and neutral endopeptidase produces effective blood pressure control in spontaneously hypertensive rats.Bratisl Lek Listy. 2005;106(12):407-11. Bratisl Lek Listy. 2005. PMID: 16642666
-
Clinical potential of endopeptidase-24.11 inhibitors in cardiovascular disease.Biochem Soc Trans. 1993 Aug;21 ( Pt 3)(3):673-8. doi: 10.1042/bst0210673. Biochem Soc Trans. 1993. PMID: 8224488 Review. No abstract available.
-
[Role of natriuretic peptides in blood pressure regulation].Nihon Rinsho. 2004 Sep;62 Suppl 9:56-9. Nihon Rinsho. 2004. PMID: 15506337 Review. Japanese. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical